Literature DB >> 16732582

Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients.

Volker Strenger1, Reinhold Kerbl, Hans Jürgen Dornbusch, Ruth Ladenstein, Peter F Ambros, Inge M Ambros, Christian Urban.   

Abstract

BACKGROUND: Urinary catecholamine metabolites are well-known to be elevated in patients with neuroblastoma. Some investigators have described different patterns in favorable and unfavorable cases. However, extended studies have not been published. PROCEDURE: We investigated urinary catecholamine patterns and their correlation to stage, biological features, and outcome in 114 consecutively clinically diagnosed neuroblastoma patients.
RESULTS: Sensitivity of vanillylmandelic acid (VMA), homovanillic acid (HVA), and dopamine (DA) was 80.7, 71.9, and 61.3%, respectively. In 91.2% of patients at least one parameter was above normal. High VMA levels were associated with favorable biological features, high DA levels were predominantly found in biologically unfavorable disease. Whereas patients with normal HVA levels had a significant better outcome, the other parameters showed no significant association with prognosis. For disseminated neuroblastoma of infancy, DA/VMA ratio proved to be helpful for the discrimination of stage 4 versus stage 4s.
CONCLUSION: Urinary catecholamines appear to be useful to give a first but important hint about the biological behavior and thus the prognosis of the underlying disease. Particularly DA/VMA ratio may serve as a tool for "biological grading"-especially in disseminated disease of infancy. In addition, it may be speculated that HVA negativity and low DA/VMA ratio may be helpful for the decision of a "wait and see" strategy in selected neuroblastoma patients with localized disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16732582     DOI: 10.1002/pbc.20888

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  20 in total

1.  Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on 123I-MIBG SPECT predict the outcome?

Authors:  Julian M M Rogasch; Patrick Hundsdoerfer; Christian Furth; Florian Wedel; Frank Hofheinz; Paul-Christian Krüger; Holger Lode; Winfried Brenner; Angelika Eggert; Holger Amthauer; Imke Schatka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-14       Impact factor: 9.236

2.  Metastatic orbital tumors in southern China during an 18-year period.

Authors:  Jianhua Yan; Shaohui Gao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-06       Impact factor: 3.117

Review 3.  Molecular Probes, Chemosensors, and Nanosensors for Optical Detection of Biorelevant Molecules and Ions in Aqueous Media and Biofluids.

Authors:  Joana Krämer; Rui Kang; Laura M Grimm; Luisa De Cola; Pierre Picchetti; Frank Biedermann
Journal:  Chem Rev       Date:  2022-01-07       Impact factor: 60.622

Review 4.  Malignant tumours of the kidney: imaging strategy.

Authors:  Anne M Smets; Jan de Kraker
Journal:  Pediatr Radiol       Date:  2010-04-30

Review 5.  Neuroblastoma: biology and staging.

Authors:  Sabine Mueller; Katherine K Matthay
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

Review 6.  123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

Authors:  Gitta Bleeker; Godelieve A M Tytgat; Judit A Adam; Huib N Caron; Leontien C M Kremer; Lotty Hooft; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2015-09-29

7.  Avoiding misdiagnosing neuroblastoma as Wilms tumor.

Authors:  Paxton V Dickson; Thomas L Sims; Christian J Streck; M Beth McCarville; Victor M Santana; Lisa M McGregor; Wayne L Furman; Andrew M Davidoff
Journal:  J Pediatr Surg       Date:  2008-06       Impact factor: 2.545

Review 8.  Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities.

Authors:  Fatima Shawraba; Hussein Hammoud; Yara Mrad; Zahraa Saker; Youssef Fares; Hayat Harati; Hisham F Bahmad; Sanaa Nabha
Journal:  Curr Treat Options Oncol       Date:  2021-09-27

Review 9.  Clinical significance of serum biomarkers in pediatric solid mediastinal and abdominal tumors.

Authors:  John A Sandoval; Linda H Malkas; Robert J Hickey
Journal:  Int J Mol Sci       Date:  2012-01-20       Impact factor: 6.208

10.  Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma.

Authors:  Giuliana Cangemi; Giorgio Reggiardo; Sebastiano Barco; Laura Barbagallo; Massimo Conte; Paolo D'Angelo; Maurizio Bianchi; Claudio Favre; Barbara Galleni; Giovanni Melioli; Riccardo Haupt; Alberto Garaventa; Maria V Corrias
Journal:  Onco Targets Ther       Date:  2012-11-30       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.